ArticleFrontiers in pharmacology2026
Astragaloside IV attenuates oxidative stress-associated mitophagy-dependent ferroptosis in peritoneal mesothelial cells via suppression of STAT3 signaling.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Peritoneal injury and subsequent fibrosis driven by oxidative stress are major contributors to peritoneal dialysis (PD) withdrawal. Ferroptosis and mitophagy are closely correlated with oxidative stress, but their roles and interplay in PD-related peritoneal injury remain incompletely defined. Astragaloside IV (AS-IV) has shown anti-fibrotic and antioxidant potential, yet its underlying mechanism in this context is not fully understood. This study aims to investigate the involvement of mitophagy and ferroptosis during PD and to evaluate whether AS-IV attenuates PD-related peritoneal injury by targeting mitophagy-dependent ferroptosis via STAT3 signaling. Methods: Mouse models of peritoneal fibrosis were established using either methylglyoxal or PD fluid (PDF). Peritoneal tissues were analyzed by histopathology and Western blotting, and serum malondialdehyde was measured. Results: PDF exposure induced oxidative stress-associated mitophagy and ferroptosis in PMCs, with evidence supporting a close association between these processes. AS-IV treatment attenuated STAT3 activation, reduced mitophagy-related changes, and alleviated ferroptosis and peritoneal injury. Conclusion: Oxidative stress-associated, mitophagy-dependent ferroptosis contributes to PD-related peritoneal injury. AS-IV attenuates this process via suppression of STAT3 signaling in PMCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.